Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 123-147

  Lepak, Alexander ^a   Andes, David ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Invasive candidiasis; Pharmacokinetics pharmacodynamics; Source control; Therapy

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; MICAFUNGIN; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BLOOD CULTURE; BRONCHOSPASM; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER INFECTION; CHILL; CLINICAL TRIAL; COMORBIDITY; DRUG ACTIVITY; DRUG CHOICE; EARLY DIAGNOSIS; EMPIRICISM; FEVER; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; HYPOXIA; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RIGOR; RISK FACTOR; SURVIVAL; TREATMENT DURATION; VOMITING;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDEMIA; CRITICAL CARE; FUNGEMIA; HUMANS; INTENSIVE CARE UNITS;

EID: 78649913406     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.11.001     Document Type: Review

References (193)

1. Wisplinghoff H., Bischoff T., Tallent S.M., et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317.
2. Hidron A.I., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29(11):996-1011.
3. Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20(1):133-163.
4. Maschmeyer G., Haas A., Cornely O.A. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007, 67(11):1567-1601.
5. Meersseman W., Lagrou K., Maertens J., et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007, 45(2):205-216.
6. Meersseman W., Vandecasteele S.J., Wilmer A., et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170(6):621-625.
7. Morris A., Lundgren J.D., Masur H., et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004, 10(10):1713-1720.
8. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34(7):909-917.
9. Husain S., Alexander B.D., Munoz P., et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003, 37(2):221-229.
10. Morgan J., Meltzer M.I., Plikaytis B.D., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26(6):540-547.
11. Pelz R.K., Lipsett P.A., Swoboda S.M., et al. Candida infections: outcome and attributable ICU costs in critically ill patients. J Intensive Care Med 2000, 15(5):255-261.
12. Zaoutis T.E., Argon J., Chu J., et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005, 41(9):1232-1239.
13. Wey S.B., Mori M., Pfaller M.A., et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988, 148(12):2642-2645.
14. Gudlaugsson O., Gillespie S., Lee K., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37(9):1172-1177.
15. Puzniak L., Teutsch S., Powderly W., et al. Has the epidemiology of nosocomial candidemia changed?. Infect Control Hosp Epidemiol 2004, 25(8):628-633.
16. Shorr A.F., Gupta V., Sun X., et al. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med 2009, 37(9):2519-2526. [quiz: 2535].
17. Rentz A.M., Halpern M.T., Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998, 27(4):781-788.
18. Arnold H.M., Micek S.T., Shorr A.F., et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010, 30(4):361-368.
19. Garey K.W., Turpin R.S., Bearden D.T., et al. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidaemia: a multi-institutional study. Int J Antimicrob Agents 2007, 29(5):557-562.
20. Zilberberg M.D., Kollef M.H., Arnold H., et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010, 10:150.
21. Miller L.G., Hajjeh R.A., Edwards J.E. Estimating the cost of nosocomial candidemia in the United States. Clin Infect Dis 2001, 32(7):1110.
22. Banerjee S.N., Emori T.G., Culver D.H., et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991, 91(3B):86S-89S.
23. Martin G.S., Mannino D.M., Eaton S., et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348(16):1546-1554.
24. Zilberberg M.D., Shorr A.F., Kollef M.H. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol 2008, 29(10):978-980.
25. Snydman D.R. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest 2003, 123(5 Suppl):500S-503S.
26. Pfaller M.A., Diekema D.J., Rinaldi M.G., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005, 43(12):5848-5859.
27. Rangel-Frausto M.S., Wiblin T., Blumberg H.M., et al. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis 1999, 29(2):253-258.
28. Trick W.E., Fridkin S.K., Edwards J.R., et al. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35(5):627-630.
29. Bouza E., Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008, 32(Suppl 2):S87-S91.
30. Horn D.L., Neofytos D., Anaissie E.J., et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009, 48(12):1695-1703.
31. Nucci M., Queiroz-Telles F., Tobon A.M., et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010, 51(5):561-570.
32. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115(2):462-474.
33. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118(1):146-155.
34. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
35. Kumar A., Ellis P., Arabi Y., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136(5):1237-1248.
36. Leibovici L., Shraga I., Drucker M., et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998, 244(5):379-386.
37. MacArthur R.D., Miller M., Albertson T., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004, 38(2):284-288.
38. Garnacho-Montero J., Ortiz-Leyba C., Herrera-Melero I., et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 2008, 61(2):436-441.
39. Garnacho-Montero J., Garcia-Garmendia J.L., Barrero-Almodovar A., et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003, 31(12):2742-2751.
40. Fraser A., Paul M., Almanasreh N., et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 2006, 119(11):970-976.
41. Valles J., Rello J., Ochagavia A., et al. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003, 123(5):1615-1624.
42. Blot S.I., Vandewoude K.H., Hoste E.A., et al. Effects of nosocomial candidemia on outcomes of critically ill patients. Am J Med 2002, 113(6):480-485.
43. Harbarth S., Ferriere K., Hugonnet S., et al. Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care. Arch Surg 2002, 137(12):1353-1359. [discussion: 1359].
44. Almirante B., Rodriguez D., Park B.J., et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43(4):1829-1835.
45. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49(9):3640-3645.
46. Garey K.W., Rege M., Pai M.P., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006, 43(1):25-31.
47. Parkins M.D., Sabuda D.M., Elsayed S., et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother 2007, 60(3):613-618.
48. Patel G.P., Simon D., Scheetz M., et al. The effect of time to antifungal therapy on mortality in candidemia associated septic shock. Am J Ther 2009, 16(6):508-511.
49. Taur Y., Cohen N., Dubnow S., et al. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010, 54(1):184-190.
50. Alexander B.D., Pfaller M.A. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006, 43(Suppl 1):15-27.
51. Ostrosky-Zeichner L., Pappas P.G. Invasive candidiasis in the intensive care unit. Crit Care Med 2006, 34(3):857-863.
52. Darouiche R.O. Candida in the ICU. Clin Chest Med 2009, 30(2):287-293. vi-vii.
53. Zilberberg M.D., Shorr A.F. Fungal infections in the ICU. Infect Dis Clin North Am 2009, 23(3):625-642.
54. Berenguer J., Buck M., Witebsky F., et al. Lysis-centrifugation blood cultures in the detection of tissue-proven invasive candidiasis. Disseminated versus single-organ infection. Diagn Microbiol Infect Dis 1993, 17(2):103-109.
55. Pappas P.G. Invasive candidiasis. Infect Dis Clin North Am 2006, 20(3):485-506.
56. Fernandez J., Erstad B.L., Petty W., et al. Time to positive culture and identification for Candida blood stream infections. Diagn Microbiol Infect Dis 2009, 64(4):402-407.
57. Ben-Ami R., Weinberger M., Orni-Wasserlauff R., et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008, 46(7):2222-2226.
58. George B.J., Horvath L.L., Hospenthal D.R. Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media. J Clin Microbiol 2005, 43(1):433-435.
59. Horvath L.L., George B.J., Murray C.K., et al. Direct comparison of the BACTEC 9240 and BacT/ALERT 3D automated blood culture systems for candida growth detection. J Clin Microbiol 2004, 42(1):115-118.
60. Sogaard M., Hjort U., Hojbjerg T., et al. Detection of candidaemia in high risk patients: can yield of blood cultures be improved by blind subculture?. Scand J Infect Dis 2006, 38(3):187-191.
61. Sendid B., Tabouret M., Poirot J.L., et al. New enzyme immunoassays for sensitive detection of circulating Candida albicans mannan and antimannan antibodies: useful combined test for diagnosis of systemic candidiasis. J Clin Microbiol 1999, 37(5):1510-1517.
62. Yera H., Sendid B., Francois N., et al. Contribution of serological tests and blood culture to the early diagnosis of systemic candidiasis. Eur J Clin Microbiol Infect Dis 2001, 20(12):864-870.
63. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41(5):654-659.
64. McMullan R., Metwally L., Coyle P.V., et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008, 46(6):890-896.
65. Vince A., Lepej S.Z., Barsic B., et al. LightCycler SeptiFast assay as a tool for the rapid diagnosis of sepsis in patients during antimicrobial therapy. J Med Microbiol 2008, 57(Pt 10):1306-1307.
66. Yanagihara K., Kitagawa Y., Tomonaga M., et al. Evaluation of pathogen detection from clinical samples by real-time polymerase chain reaction using a sepsis pathogen DNA detection kit. Crit Care 2010, 14(4):R159.
67. Avni T., Leibovici L., Paul M. PCR diagnosis of invasive candidiasis: systematic review and meta-analysis. J Clin Microbiol 2010, 48(2):489-496.
68. Wey S.B., Mori M., Pfaller M.A., et al. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989, 149(10):2349-2353.
69. Blumberg H.M., Jarvis W.R., Soucie J.M., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33(2):177-186.
70. Diekema D.J., Pfaller M.A. Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004, 25(8):624-626.
71. Munoz P., Burillo A., Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000, 15(2):83-90.
72. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003, 16(6):533-537.
73. Ostrosky-Zeichner L. Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004, 23(10):739-744.
74. Paphitou N.I., Ostrosky-Zeichner L., Rex J.H. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005, 43(3):235-243.
75. Sobel J.D., Rex J.H. Invasive candidiasis: turning risk into a practical prevention policy?. Clin Infect Dis 2001, 33(2):187-190.
76. Piarroux R., Grenouillet F., Balvay P., et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004, 32(12):2443-2449.
77. Wenzel R.P. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995, 20(6):1531-1534.
78. Wenzel R.P., Gennings C. Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 2005, 41(Suppl 6):S389-S393.
79. Guery B.P., Arendrup M.C., Auzinger G., et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis. Intensive Care Med 2009, 35(1):55-62.
80. Chow J.K., Golan Y., Ruthazer R., et al. Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med 2008, 36(7):1993-1998.
81. Hoerauf A., Hammer S., Muller-Myhsok B., et al. Intra-abdominal Candida infection during acute necrotizing pancreatitis has a high prevalence and is associated with increased mortality. Crit Care Med 1998, 26(12):2010-2015.
82. Pyrgos V., Ratanavanich K., Donegan N., et al. Candida bloodstream infections in hemodialysis recipients. Med Mycol 2009, 47(5):463-467.
83. Fraser V.J., Jones M., Dunkel J., et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992, 15(3):414-421.
84. Marr K.A., Seidel K., White T.C., et al. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000, 181(1):309-316.
85. Dupont H., Bourichon A., Paugam-Burtz C., et al. Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis?. Crit Care Med 2003, 31(3):752-757.
86. Prentice H.G., Kibbler C.C., Prentice A.G. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000, 110(2):273-284.
87. Pittet D., Monod M., Suter P.M., et al. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220(6):751-758.
88. Leon C., Ruiz-Santana S., Saavedra P., et al. A bedside scoring system (" Candida score" ) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34(3):730-737.
89. Leon C., Ruiz-Santana S., Saavedra P., et al. Usefulness of the " Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009, 37(5):1624-1633.
90. Ostrosky-Zeichner L., Sable C., Sobel J., et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26(4):271-276.
91. Faiz S., Neale B., Rios E., et al. Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit. Eur J Clin Microbiol Infect Dis 2009, 28(6):689-692.
92. ClinicalTrials.gov. Randomized study of caspofungin prophylaxis followed by pre-emptive therapy for invasive candidiasis in the ICU (MSG-01) 2010. Available at: Accessed August 23, 2010. http://clinicaltrials.gov/ct2/show/NCT00520234.
93. Andes D. Pharmacokinetics and pharmacodynamics of antifungals. Infect Dis Clin North Am 2006, 20(3):679-697.
94. Denning D.W. Echinocandin antifungal drugs. Lancet 2003, 362(9390):1142-1151.
95. Dodds Ashley E.S., Lewis R., Lewis J.S., et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006, 43:S28-S39.
96. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010, 67(2):162-171.
97. Pfaller M.A., Diekema D.J., Gibbs D.L., et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007, 45(6):1735-1745.
98. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347(25):2020-2029.
99. Kabbara N., Lacroix C., Peffault de Latour R., et al. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 2008, 93(4):639-640.
100. Brielmaier B.D., Casabar E., Kurtzeborn C.M., et al. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 2008, 28(1):64-73.
101. Forrest G.N., Weekes E., Johnson J.K. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 2008, 56(2):126-129.
102. Cheung C., Guo Y., Gialanella P., et al. Development of candidemia on caspofungin therapy: a case report. Infection 2006, 34(6):345-348.
103. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010, 48(7):2373-2380.
104. Rex J.H., Bennett J.E., Sugar A.M., et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994, 331(20):1325-1330.
105. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36(10):1221-1228.
106. Kullberg B.J., Sobel J.D., Ruhnke M., et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366(9495):1435-1442.
107. Reboli A.C., Rotstein C., Pappas P.G., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356(24):2472-2482.
108. Kuse E.R., Chetchotisakd P., da Cunha C.A., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369(9572):1519-1527.
109. Pappas P.G., Rotstein C.M., Betts R.F., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45(7):883-893.
110. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535.
111. Andes DR, Safdar N, Baddley J, et al. Impact of therapy on mortality across Candida spp in patients with invasive candidiasis from randomized clinical trials: a patient level analysis. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston (MA), September 12-15, 2010.
112. Eriksson U., Seifert B., Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001, 322(7286):579-582.
113. Uehara R.P., Sa V.H., Koshimura E.T., et al. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundacao ABC. Sao Paulo Med J 2005, 123(5):219-222.
114. Speich R., Dutly A., Naef R., et al. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. Swiss Med Wkly 2002, 132(31-32):455-458.
115. Schulenburg A., Sperr W., Rabitsch W., et al. Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies. Leuk Lymphoma 2005, 46(8):1163-1167.
116. Peleg A.Y., Woods M.L. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004, 54(4):803-808.
117. Falci D.R., Lunardi L.W., Ramos C.G., et al. Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: analysis of safety and fungicidal activity. Clin Infect Dis 2010, 50(5):e26-e29.
118. Imhof A., Walter R.B., Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003, 36(8):943-951.
119. Kethireddy S., Andes D. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007, 3(4):573-581.
120. Andes D., Safdar N., Marchillo K., et al. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006, 50(2):674-684.
121. Groll A.H., Lyman C.A., Petraitis V., et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006, 50(10):3418-3423.
122. Groll A.H., Giri N., Petraitis V., et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis 2000, 182(1):274-282.
123. Lewis R.E., Liao G., Hou J., et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2007, 51(4):1253-1258.
124. Janknegt R., de Marie S., Bakker-Woudenberg I.A., et al. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 1992, 23(4):279-291.
125. Brooks R.G. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch Intern Med 1989, 149(10):2226-2228.
126. Gauthier G.M., Nork T.M., Prince R., et al. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005, 41(3):e27-e28.
127. Klevay M.J., Horn D.L., Neofytos D., et al. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2009, 64(2):152-157.
128. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26(1):1-10. [quiz: 11-2].
129. Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin 2009, 25(4):733-751. viii.
130. Lepak A., Andes D. Pharmacodynamics of antifungal drugs: a strategy to optimize efficacy. Curr Fungal Infect Rep 2008, 2:12-19.
131. Andes D., Stamsted T., Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001, 45(3):922-926.
132. Lewis R.E., Wiederhold N.P., Klepser M.E. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 2005, 49(3):945-951.
133. Ernst E.J., Klepser M.E., Pfaller M.A. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother 2000, 44(4):1108-1111.
134. Turnidge J.D., Gudmundsson S., Vogelman B., et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts. J Antimicrob Chemother 1994, 34(1):83-92.
135. Hong Y., Shaw P.J., Nath C.E., et al. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob Agents Chemother 2006, 50(3):935-942.
136. Andes D., van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999, 43(9):2116-2120.
137. Louie A., Drusano G.L., Banerjee P., et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998, 42(5):1105-1109.
138. Klepser M.E., Malone D., Lewis R.E., et al. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000, 44(7):1917-1920.
139. Andes D., Marchillo K., Stamstad T., et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003, 47(10):3165-3169.
140. Andes D., Marchillo K., Stamstad T., et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003, 47(4):1193-1199.
141. Andes D., Marchillo K., Conklin R., et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004, 48(1):137-142.
142. Baddley J.W., Patel M., Bhavnani S.M., et al. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob Agents Chemother 2008, 52(9):3022-3028.
143. Clancy C.J., Yu V.L., Morris A.J., et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005, 49(8):3171-3177.
144. Lee S.C., Fung C.P., Huang J.S., et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000, 44(10):2715-2718.
145. Pai M.P., Turpin R.S., Garey K.W. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007, 51(1):35-39.
146. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997, 24(2):235-247.
147. Rodriguez-Tudela J.L., Almirante B., Rodriguez-Pardo D., et al. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother 2007, 51(10):3599-3604.
148. Takakura S., Fujihara N., Saito T., et al. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis 2004, 23(5):380-388.
149. Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston (MA), September 12-15, 2010.
150. Pfaller M.A., Diekema D.J., Rex J.H., et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006, 44(3):819-826.
151. Pascual A., Calandra T., Bolay S., et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008, 46(2):201-211.
152. Smith J., Safdar N., Knasinski V., et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006, 50(4):1570-1572.
153. Denning D.W., Ribaud P., Milpied N., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34(5):563-571.
154. Trifilio S., Pennick G., Pi J., et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007, 109(8):1532-1535.
155. Andes D., Pascual A., Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009, 53(1):24-34.
156. Andes D., Marchillo K., Lowther J., et al. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003, 47(4):1187-1192.
157. Andes D., Diekema D.J., Pfaller M.A., et al. In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008, 52(2):539-550.
158. Andes D.R., Diekema D.J., Pfaller M.A., et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother 2008, 52(10):3497-3503.
159. Ernst E.J., Roling E.E., Petzold C.R., et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002, 46(12):3846-3853.
160. Gumbo T., Drusano G.L., Liu W., et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob Agents Chemother 2006, 50(11):3695-3700.
161. Gumbo T., Drusano G.L., Liu W., et al. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrob Agents Chemother 2007, 51(3):968-974.
162. Louie A., Deziel M., Liu W., et al. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005, 49(12):5058-5068.
163. Walsh T.J., Lee J.W., Kelly P., et al. Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis. Antimicrob Agents Chemother 1991, 35(7):1321-1328.
164. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Clin Microbiol Rev, in press.
165. Andes D., Diekema D.J., Pfaller M.A., et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 2010, 54(6):2497-2506.
166. Ambrose P.G., Bhavnani S.M., Rubino C.M., et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007, 44(1):79-86.
167. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008, 46(8):2620-2629.
168. Andes DR, Ambrose PG, Hammel JP, et al. Exposure-response (E-R) relationships for efficacy of micafungin in patients with invasive candidiasis (IC). Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 12-15, 2009.
169. Clinical breakpoints for Candida and the echinocandins. Clinical and Laboratory Standards Institute Subcommittee on Antifungal Susceptibility Tests. Atlanta 2010.
170. Mermel L.A., Allon M., Bouza E., et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 49(1):1-45.
171. Mermel L.A., Farr B.M., Sherertz R.J., et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001, 32(9):1249-1272.
172. Nucci M., Colombo A.L., Silveira F., et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998, 19(11):846-850.
173. Pasqualotto A.C., de Moraes A.B., Zanini R.R., et al. Analysis of independent risk factors for death among pediatric patients with candidemia and a central venous catheter in place. Infect Control Hosp Epidemiol 2007, 28(7):799-804.
174. Labelle A.J., Micek S.T., Roubinian N., et al. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36(11):2967-2972.
175. Raad I., Hanna H., Boktour M., et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 2004, 38(8):1119-1127.
176. Rex J.H., Bennett J.E., Sugar A.M., et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995, 21(4):994-996.
177. Liu C.Y., Huang L.J., Wang W.S., et al. Candidemia in cancer patients: impact of early removal of non-tunneled central venous catheters on outcome. J Infect 2009, 58(2):154-160.
178. Horn D.L., Ostrosky-Zeichner L., Morris M.I., et al. Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. Eur J Clin Microbiol Infect Dis 2010, 29(2):223-229.
179. Nucci M., Silveira M.I., Spector N., et al. Risk factors for death among cancer patients with fungemia. Clin Infect Dis 1998, 27(1):107-111.
180. Rodriguez D., Park B.J., Almirante B., et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. Clin Microbiol Infect 2007, 13(8):788-793.
181. Velasco E., Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis 2008, 27(11):1071-1078.
182. Weinberger M., Leibovici L., Perez S., et al. Characteristics of candidaemia with Candida albicans compared with non-albicans Candida species and predictors of mortality. J Hosp Infect 2005, 61(2):146-154.
183. Nucci M., Anaissie E., Betts R.F., et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010, 51(3):295-303.
184. Essman T.F., Flynn H.W., Smiddy W.E., et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997, 28(3):185-194.
185. Rex J.H., Sobel J.D. Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001, 32(8):1191-1200.
186. Viscoli C. Antifungal prophylaxis and pre-emptive therapy. Drugs 2009, 69(Suppl 1):75-78.
187. Playford E.G., Lipman J., Sorrell T.C. Prophylaxis, empirical and preemptive treatment of invasive candidiasis. Curr Opin Crit Care 2010, 16(5):470-474.
188. Rotstein C. Invasive candidiasis in the ICU: prophylaxis versus preemptive treatment. Curr Infect Dis Rep 2008, 10(6):454-458.
189. Playford E.G., Webster A.C., Sorrell T.C., et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006, 57(4):628-638.
190. Cruciani M., de Lalla F., Mengoli C. Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med 2005, 31(11):1479-1487.
191. Ho K.M., Lipman J., Dobb G.J., et al. The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit Care 2005, 9(6):R710-R717.
192. Hughes W.T., Armstrong D., Bodey G.P., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002, 34(6):730-751.
193. Schuster M.G., Edwards J.E., Sobel J.D., et al. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann Intern Med 2008, 149(2):83-90.